INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc.

Rafael Holdings fell $0.71 per share, or 34.98%, to $1.32 on September 30, 2026, after its Cyclo Therapeutics subsidiary reported that a 94-patient Phase 3 study of Trappsol Cyclo did not achieve statistical significance on its primary endpoint. Pomerantz LLP said it is investigating potential securities-law claims involving Rafael and certain officers or directors; the announcement is an investigation, not a finding of wrongdoing.

Analysis

The legal headline is a secondary risk, not new evidence about the drug: a law-firm investigation/solicitation is not a filed case or finding of misconduct. The primary economic damage is the failed Phase 3 endpoint, already reflected in a sharp repricing. The investigation can nevertheless prolong the discount by raising uncertainty around disclosure, governance, and management credibility—especially if the full study data do not support a clear explanation of the miss. Near term, expect event-driven volatility and potential liquidity pressure; over 1–3 months, watch for a formal complaint, company response, and detailed trial results. Over 6–18 months, value depends on whether the program has a credible path forward or whether capital and attention shift to other Rafael assets; the article provides no basis to quantify either outcome. Avoid treating the subsidiary’s trial result as a conclusion about all of Rafael’s businesses. The contrarian point: the lawsuit notice itself may be over-read as a fresh fundamental shock, while the market may still be underestimating the implications of a pivotal endpoint miss. Any recovery thesis needs verifiable evidence—complete data, a regulatory path, and funding runway—not headline optimism.

Key Decisions for Investors

• Do not add to RFL solely on the assumption that the investigation will be dismissed or is immaterial; first verify whether a complaint has been filed, what alleged statements it targets, and whether Rafael issues a substantive response.
• For existing exposure, size risk around the underlying clinical and balance-sheet uncertainty rather than the law-firm announcement. Review the full Phase 3 dataset, cash/runway, and the value and funding needs of Rafael’s other assets before deciding whether to hold.
• No immediate short recommendation after the reported 35% single-day decline: the trial miss is already a major repricing event, and the article supplies no valuation, borrow, or liquidity data. Consider a short only if subsequent disclosures worsen the program outlook or reveal material disclosure inconsistencies; cap risk against a credible data clarification or alternative development path.
• Watch for a formal securities complaint, full trial data and management guidance over the next 1–3 months. A credible regulatory/development plan and adequate runway would weaken the bearish thesis; additional negative data, a material guidance change, or evidence of inadequate disclosure would strengthen it.